Results 261 to 270 of about 3,069,445 (313)

Trends, Dynamicity in Collaboration, and Impact on Perfluorooctanoic Acid and Cancer Research: A Scientometric Study. [PDF]

Indian J Community Med
Espinoza-Carhuancho F, Temoche A, Alvitez J, Medina J, Mauricio-Vilchez C, Quispe-Tasayco L, Mayta-Tovalino F.   +6 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Marine-Derived Ligands of Nicotinic Acetylcholine Receptors in Cancer Research. [PDF]

Mar Drugs
Kasheverov IE, Shelukhina IV, Utkin YN, Tsetlin VI.   +3 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial. [PDF]

BJC Rep
Malcomson FC, Shams-White MM, Reedy J, Huang WY, Moore SC, Loftfield E.   +5 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Machine Learning Models for Cancer Research: A Narrative Review of Bulk RNA-Seq Applications. [PDF]

Int J Mol Sci
Pudova EA, Pavlov VS, Guvatova ZG, Fedorova MS, Shegai PV, Kudryavtseva AV, Snezhkina AV.   +6 more
europepmc   +1 more source

G protein-coupled receptors in prostate cancer: research progress and therapeutic targets. [PDF]

Front Cell Dev Biol
Xiong W, Zhou B, Shi J, Ni D, Xiong Z.
europepmc   +1 more source

Methods and Guidelines for Metabolism Studies: Applications to Cancer Research. [PDF]

Int J Mol Sci
Li M, Amend SR, Pienta KJ.
europepmc   +1 more source

Prostate Cancer-Research Advances in Early Detection. [PDF]

J Clin Med
Czerw A, Deptała A, Głowacka M, Partyka O, Pajewska M, Czerw N, Badowska-Kozakiewicz A, Sygit K, Kopczyński Z, Czarnywojtek P, Gąska I, Kaczmarski M, Banaś T, Grochans E, Grochans S, Cybulska AM, Schneider-Matyka D, Bandurska E, Ciećko W, Dykowska G, Sienkiewicz Z, Drobnik J, Pobrotyn P, Grata-Borkowska U, Furtak-Pobrotyn J, Sierocka A, Marczak M, Pokorna-Kalwak D, Kozlowski R.   +28 more
europepmc   +1 more source